B99430AD-6309-4B90-A0AA-A5B2FA746246
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.851511169513797
- age_years
- 59
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.959 |
| 2 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.957 |
| 3 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.956 |
| 4 | SRR934883 | — | — | 0.955 |
| 5 | E24D233D-71BD-4EC2-A671-375917F24E5C | — | — | 0.954 |
| 6 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.953 |
| 7 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.952 |
| 8 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.950 |
| 9 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.948 |
| 10 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.563 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.554 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.527 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.514 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.452 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.439 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.427 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.419 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.415 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.411 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.410 | Inavolisib | — uncovered |
| APOPTOSIS | 0.408 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.397 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.393 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.385 | Inavolisib | — uncovered |
| HYPOXIA | 0.383 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.383 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.373 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.361 | Idelalisib | — uncovered |